Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...
On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $96.57 which represents a decrease of $-1.33 or -1.36% from the prior close of $97.9. The stock opened at $96.05 and ...
At the start of this year, I observed that shares of Gilead Sciences, Inc. (NASDAQ:GILD) saw a downward re-rating after the ...
Inc. Matt Biegler; Analyst; Oppenheimer and Co. Good afternoon, everyone, and welcome to Gilead's third-quarter 2024 earnings conference call. My name is Rebecca and I'll be your host for today in ...
On Thursday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $97.9 which represents a slight increase of $6.21 or 6.77% from the prior close of $91.69. The stock opened at ...
Full-Year Non-GAAP EPS Guidance: $4.25 to $4.45. Gilead Sciences Inc (NASDAQ:GILD) reported a strong quarter with a 9% growth in HIV sales year-over-year, driven by higher demand and pricing.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Jefferies London Heal ...
MISSISSAUGA — Gilead Sciences Canada, Inc. (Gilead Canada) announced that Paul Petrelli joined the organization as Vice ...
FDA grants accelerated approval to Gilead's Livdelzi for PBC FOSTER CITY, Calif. - Gilead Sciences, Inc. (NASDAQ:GILD) has received accelerated approval from the U.S. Food and Drug Administration ...
Gilead Sciences, Inc. (NASDAQ:GILD) Q3 2024 Earnings Call Transcript November 6, 2024 Gilead Sciences, Inc. beats earnings expectations. Reported EPS is $2.02, expectations were $1.53. Operator: Good ...
Fintel reports that on November 8, 2024, Maxim Group downgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Buy to ...
FOSTER CITY, Calif. (AP) — FOSTER CITY, Calif. (AP) — Gilead Sciences Inc. (GILD) on Wednesday reported third-quarter net income of $1.25 billion. On a per-share basis, the Foster City, ...